10-K: Qualigen Therapeutics Faces Delisting Amidst Deepening Financial Woes and Strategic Shifts

Qualigen Therapeutics, an early-clinical-stage oncology company, reported a significant net loss and accumulated deficit for 2024, raising substantial doubt about its ability to continue as a going concern, compounded by a Nasdaq delisting notice and a slowdown in its core therapeutic programs.

Summary

• Qualigen Therapeutics is an early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer, with lead programs QN-302 (Phase 1a clinical trial for pancreatic cancer) and Pan-RAS (preclinical).
• The company entered into a Co-Development Agreement with Marizyme, Inc. in April 2024, investing $500,000 and advancing an additional $1,250,000 via an 18% demand promissory note, with total funding up to $1,750,000, in return for 33% royalties on DuraGraft Net Sales, capped at double the funding, after $500,000 cumulative U.S. Net Sales.
• Qualigen sold its former FastPack diagnostics business (Qualigen, Inc. subsidiary) to Chembio Diagnostics, Inc. for $5.4 million in cash on July 20, 2023; a $450,000 escrow from this sale was settled early on June 4, 2024, resulting in $350,000 paid to the company and a $100,000 loss from discontinued operations.
• The company reduced its ownership in NanoSynex from approximately 52.8% to 39.90% by surrendering preferred shares and eliminating future funding obligations.
• A 1-for-50 reverse stock split was implemented on November 5, 2024, reducing shares outstanding from 36,837,020 to 736,431, aimed at regaining Nasdaq compliance.
• Qualigen raised approximately $8.0 million in new equity in 2024, including $4.6 million from Series A-2 Preferred Stock, $3.0 million from common stock and prefunded warrants, and $0.4 million from warrant exercises.
• The company also raised $1.5 million in new convertible debt and $2.0 million in short-term debt in 2024, with $1.1 million in convertible debt exchanged for Series A-2 Preferred Stock and $0.5 million repaid in cash, and the $2.0 million short-term debt also repaid in cash.
• Net loss for the year ended December 31, 2024, was $6.3 million, a decrease from $13.8 million in 2023.
• The accumulated deficit stood at $123.1 million as of December 31, 2024.
• Cash and cash equivalents were $1.2 million as of December 31, 2024, with cash balances expected to fund operations only into the third quarter of 2025.
• A material weakness in internal control over financial reporting was identified for the 2024 audit, related to insufficient accounting department resources and lack of formalized documentation, leading to the late filing of the 10-K.
• The company received a Nasdaq notice of delisting due to the delinquent 10-K filing and has appealed the decision.
• As of June 24, 2025, the company reported having no employees.

Sentiment

Score: 2

Explanation: The company faces severe financial distress, evidenced by recurring losses, a substantial accumulated deficit, and a 'going concern' qualification from its auditors. Cash reserves are critically low, expected to last only into Q3 2025. The company has slowed its primary therapeutic development program (QN-302) due to financial constraints and is in arrears on accounts payable. Furthermore, it received a Nasdaq delisting notice due to a late filing, stemming from identified material weaknesses in internal controls. While capital was raised, it appears to be a stop-gap measure rather than a solution to long-term viability without further significant funding.

Positives

• QN-302 received Orphan Drug Designation from the FDA on January 9, 2023, for pancreatic cancer, which provides advantages such as seven-year marketing exclusivity, regulatory support, a 25% federal tax credit for clinical research expenses, and potential waiver of PDUFA application fees (approx. $3.2 million savings).
• The FDA cleared the Investigational New Drug (IND) application for QN-302 on August 1, 2023, and the first patient in the Phase 1a clinical trial was dosed on November 1, 2023.
• Preclinical in-vivo studies suggest QN-302 has activity in gemcitabine-resistant pancreatic ductal adenocarcinoma (PDAC) and showed longer survival duration in a mouse model compared to historical gemcitabine results.
• The company successfully raised approximately $8.0 million in new equity and $3.5 million in new debt (net of repayments) during 2024, providing crucial funding.
• Net loss significantly decreased to $6.3 million in 2024 from $13.8 million in 2023.
• General and administrative expenses decreased by $1.9 million (from $6.1 million in 2023 to $4.2 million in 2024), primarily due to reduced stock-based compensation, payroll, and insurance expenses.
• Research and development expenses decreased by $4.0 million (from $5.2 million in 2023 to $1.2 million in 2024), mainly due to reduced preclinical, clinical research, and licensing costs for QN-302 and Pan-RAS, and lower payroll expenses.
• The $450,000 escrow account from the Qualigen, Inc. sale was settled early, providing $350,000 in cash proceeds to the company.

Negatives

• The company incurred a net loss of $6.3 million for the year ended December 31, 2024, and has an accumulated deficit of $123.1 million.
• A working capital deficiency and stockholders' equity deficit raise substantial doubt about the company's ability to continue as a going concern.
• Cash balances are expected to fund operations only into the third quarter of 2025, indicating a critical liquidity challenge.
• The company is in arrears on accounts payable to important partners, with net accounts payable exceeding $1.6 million as of December 31, 2024.
• Development of therapeutic products, including the QN-302 Phase 1 Study, was slowed beginning in the second quarter of 2024 due to financial constraints.
• A material weakness in internal control over financial reporting was identified for the 2024 audit, leading to adjustments and the late filing of the 10-K.
• The company received a notice from Nasdaq regarding delisting due to the delinquent 10-K filing, although an appeal has been filed.
• A $360,000 credit loss expense was recognized on short-term notes receivable from Marizyme, reflecting concerns about the recoverability of these advances.
• The out-license agreement for the Pan-RAS program with Pan-RAS Holdings, Inc. was terminated because Pan-RAS Holdings did not complete the closing.
• All efforts on previous programs (QN-247, QN-165, and Selective Target Antigen Removal System (STARS)) have been discontinued.
• The company reported having no employees as of June 24, 2025, which could impact operational capacity and future development.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to significant losses, accumulated deficit, and negative cash flows.
• Inability to obtain sufficient financing on acceptable terms could materially adversely affect the company's financial condition, results of operations, and business prospects.
• Failure to develop or maintain effective internal controls over financial reporting or difficulties in implementing/improving them could harm operating results and prevent meeting reporting obligations.
• A material weakness in internal control over financial reporting was identified, specifically related to a lack of sufficient accounting department personnel for adequate segregation of duties, ineffective Information Technology General Controls (ITGC) for financial accounting system access, and lack of formalized documentation of processes and controls.
• Continued uncertain economic conditions, including inflation and the risk of a global recession, could impair the company's ability to forecast and harm its business, operating results, financial condition, and cash flows.
• Computer system failures, cyberattacks, or deficiencies in cybersecurity could disrupt operations, lead to data loss/damage, incur material legal claims, and damage reputation.
• Future growth may be limited by the company's ability to attract and retain skilled employees, successfully position and market product candidates, protect intellectual property, capitalize on third-party opportunities, and acquire sufficient funding.
• The need for additional financing for capital expenditures, working capital, research and development, sales and marketing, and operating losses creates financial leverage if debt is incurred, or dilution if equity is sold, with no assurance of availability on acceptable terms.
• Geopolitical conditions, including acts of war or terrorism (e.g., in Ukraine and Israel), could adversely affect operations and financial results by increasing costs, disrupting supply chains, reducing sales, or impairing capital raising.
• The company is subject to litigation, such as the lawsuit filed by Lifesci Capital LLC seeking $503,483, which could result in significant expenses and negatively impact the business.
• Even if development efforts are successful, the company may not obtain regulatory approval for any product candidates in the U.S. or other jurisdictions, preventing commercialization.
• Regulatory approval processes are lengthy, time-consuming, and inherently unpredictable, with potential for delays or rejection due to changing policies, regulations, or varying interpretations of data.
• Changes in product candidate manufacturing or formulation may result in additional costs or delays, potentially requiring additional testing or regulatory approvals.
• The company may be subject to substantial fines, penalties, or enforcement actions, including criminal actions, if determined to be promoting products for unapproved or off-label uses.
• Any product candidate receiving regulatory approval will be subject to extensive and ongoing requirements and review, resulting in significant additional expense and limitations on manufacturing and marketing.
• Significant competition from other biopharmaceutical and biotechnology companies, academic institutions, and research organizations may result in others developing or commercializing products more quickly or successfully.
• Inability to establish effective marketing, sales, and distribution capabilities or enter into agreements with third parties could limit revenues and prevent profitability.
• The novel approach of the company's product candidates makes it difficult to predict the time and cost of development, with no assurance that development problems can be solved without significant delays or unanticipated costs.
• If product candidates do not achieve broad market acceptance, revenues from sales may be limited, and the company may never become profitable.
• Successful commercialization depends on adequate reimbursement levels and pricing policies from government authorities and health insurers, which are uncertain and subject to cost control initiatives.
• The size of the potential market for product candidates is difficult to estimate, and inaccurate assumptions could lead to smaller actual markets.
• A large number of authorized but unissued shares of common stock (approximately 224.3 million) will dilute existing ownership positions when issued.
• The common stock may be affected by limited trading volume and price fluctuations, which could adversely impact its value.
• Delisting of the common stock from Nasdaq would have a serious negative effect on any future financing efforts.

Future Outlook

The company expects to continue incurring net losses and negative cash flow from operations, with current cash balances projected to fund operations only into the third quarter of 2025. Additional cash resources are required to continue and complete the QN-302 Phase 1a clinical trial. Management and the board are strategically reviewing plans to advance the therapeutics pipeline and will ramp up development when properly funded through either the capital markets or strategic partnerships. The company intends to invest more resources into improving its cybersecurity posture and will continue to assess and update measures in response to emerging threats, potentially considering cybersecurity insurance. The company does not expect to pay cash dividends in the foreseeable future, and there is no assurance that future financing will be available on favorable terms or at all. Delisting from Nasdaq would seriously negatively affect future financing efforts, and there is no assurance that profitable operations will ever be achieved.

Management Comments

• "To experience losses while therapeutic products are still under development is, of course, typical for biotechnology companies."
• "Given our financial situation, the company slowed the development of the aforementioned therapeutic products beginning in the second quarter 2024."
• "Management and the board are strategically reviewing plans on how to best advance our therapeutics pipeline, and will ramp up development when properly funded through either the capital markets or strategic partnerships."
• "We believe that no amount is owed to Lifesci under the agreement at issue and are vigorously defending against the claims."
• "We intend to invest more resources into improving our assessment and response to cybersecurity risk in the future."
• "Our goal is to establish a cybersecurity framework that is commensurate with our size, complexity and the nature of our operations, thereby reducing our exposure to cybersecurity risks."
• "The Board (or designated committee or officer) will receive periodic updates on cybersecurity risks, including emerging threats, mitigation efforts and incident response activities."

Industry Context

Qualigen Therapeutics operates in the high-risk, high-reward early-clinical-stage therapeutics sector, specifically focusing on oncology. The company's pursuit of novel approaches like G-quadruplexes (G4)-selective transcription inhibitors and Pan-RAS oncogene protein-protein interaction inhibitors is characteristic of the industry's drive for innovative treatments, though these entail long development cycles and significant R&D costs. The receipt of Orphan Drug Designation for QN-302 for pancreatic cancer provides a competitive advantage within the rare disease segment, offering regulatory and financial incentives. The strategic divestiture of its diagnostics business and reduction of interest in NanoSynex aligns with a common biotech strategy to streamline operations and focus on core drug development. However, the company's severe financial distress, including a 'going concern' warning and Nasdaq delisting notice, highlights the intense capital demands and inherent financial fragility often seen in early-stage biotech companies that are pre-revenue from product sales and heavily reliant on external financing.

Comparison to Industry Standards

• QN-302, a G4-selective transcription inhibitor, showed a longer survival duration in a KPC genetic mouse model for pancreatic cancer than gemcitabine, which is the current standard of care for PDAC, has historically shown in preclinical studies.
• The company's financial situation, characterized by recurring losses, an accumulated deficit of $123.1 million, and a 'going concern' qualification, is typical for early-stage biotechnology companies that are pre-revenue from product sales and heavily reliant on external financing to fund research and development.
• The severity of the 'going concern' warning and the Nasdaq delisting notice due to a late filing indicate a more distressed financial position compared to a typical well-funded early-stage biotech company, suggesting significant challenges in securing and maintaining capital.

Management Changes

Corporate Governance

Legal Proceedings

• On January 29, 2025, Lifesci Capital LLC filed a lawsuit against the company in the U.S. District Court for the Southern District of New York, alleging breach of contract and seeking damages of $503,483 in connection with offerings of the company's common stock during the tail period of an engagement agreement.
• The company filed its answer on March 17, 2025, denying the material allegations and asserting various affirmative defenses.
• As of June 26, 2025, the matter is in the discovery phase, and the company disputes that any amount is owed and is vigorously defending the lawsuit.

Related Party Transactions

• **Alpha Capital Anstalt (Alpha)**: The company issued an 8% Senior Convertible Debenture for $3,300,000 to Alpha on December 22, 2022. The conversion price was reduced multiple times, and Alpha converted $1,111,078 principal into 16,834 common shares in 2023, and $660,000 into 45,496 common shares in 2024. The remaining $758,922 principal was voluntarily converted into 58,378 common shares in June and July 2024, fully extinguishing the obligation.
• **Alpha Capital Anstalt (Alpha)**: A warrant to purchase 50,000 common shares was issued to Alpha on December 22, 2022. Its exercise price was repriced from $82.50 to $36.50, then to $13.00, and finally to $6.50. Alpha partially exercised this warrant for 31,998 shares in 2024, generating $416,000 in proceeds.
• **Alpha Capital Anstalt (Alpha)**: An 8% Convertible Debenture for $550,000 was issued to Alpha on February 27, 2024. Its conversion price was reduced from $30.56 to $6.50. Alpha partially converted $50,979 into 7,842 common shares. The remaining $530,839 principal and accrued interest were repaid in cash on November 20, 2024.
• **Alpha Capital Anstalt (Alpha)**: A warrant to purchase 18,001 common shares was issued to Alpha on February 27, 2024, with an exercise price initially at $13.00, later repriced to $6.50. A portion was temporarily reclassified to liabilities due to insufficient authorized shares, then back to equity after shareholder approval.
• **Alpha Capital Anstalt (Alpha)**: An option to purchase an additional $1.1 million in 8% Convertible Debentures was granted to Alpha, which Alpha assigned to Yi Hua Chen in April 2024.
• **Yi Hua Chen (Chen)**: An 8% Convertible Debenture for $1,100,000 was issued to Chen on April 12, 2024, after Alpha assigned the option. Its conversion price was reduced from $30.56 to $6.50. The entire outstanding principal and accrued interest of approximately $1,154,000 were converted into 1,154 shares of Series A-2 Preferred Stock on November 20, 2024.
• **Yi Hua Chen (Chen)**: A warrant to purchase 36,001 common shares was issued to Chen on April 12, 2024, with an exercise price initially at $13.00, later repriced to $6.50. This warrant was initially liability classified due to insufficient authorized shares, then reclassified to equity after shareholder approval.
• **Marizyme, Inc.**: The company entered a Co-Development Agreement on April 11, 2024, agreeing to pay Funding Payments up to $1,750,000 and a $200,000 Exclusivity Fee. $500,000 in funding and the exclusivity fee were paid on April 12, 2024. The company advanced an additional $2,257,400 to Marizyme in 2024 via 18% demand promissory notes, with $113,292 in accrued interest and a $360,000 allowance for credit losses recorded. An additional $1,518,500 was advanced from January through June 2025.
• **NanoSynex, Ltd.**: The company owned a minority interest (39.90% as of December 31, 2023) after deconsolidating the subsidiary on July 20, 2023. The carrying value of the retained investment was zero as of December 31, 2024 and 2023.
• **IR Agency, LLC**: A consulting agreement was entered on October 9, 2024, for investor relations services. A fee of $800,000 was paid upon the closing of the November 2024 Preferred Stock Offering for services to be rendered until the third quarter of 2025.
• **Former Board Members**: Richard David, Sidney Emery, Jr., Kurt Kruger, and Ira Ritter received restricted common stock as 'other compensation' upon their resignation in July 2024, in full settlement of remaining payment obligations.
• **Christopher Lotz (Former CFO)**: A consulting agreement was entered into with Christopher Lotz, effective October 8, 2024, for a period of six months, with fees earned and paid in 2024 disclosed in the Executive Compensation section.

Stakeholder Impact

• **Shareholders**: Face significant dilution from past and potential future capital raises due to a large number of authorized but unissued shares. The 1-for-50 reverse stock split was implemented to maintain Nasdaq listing, but the subsequent delisting notice and appeal create uncertainty. The 'going concern' warning indicates a high risk of total loss of investment.
• **Employees**: Experienced a reduction in force, leading to decreased payroll expenses. The company reported having no employees as of June 24, 2025, which raises concerns about operational capacity and future development execution.
• **Creditors/Partners**: The company is in arrears on accounts payable to important partners, totaling over $1.6 million, which could strain relationships and impact the ability to secure future services or supplies.
• **Management**: Significant changes in executive leadership and board composition have occurred, potentially impacting strategic direction and stability. Executive compensation practices include a claw-back policy for erroneous incentive-based compensation.

Next Steps

• Obtain additional funding to continue and complete the QN-302 Phase 1a clinical trial.
• Strategically review plans to best advance the therapeutics pipeline.
• Ramp up development of therapeutic products when properly funded through capital markets or strategic partnerships.
• Continue efforts to remediate identified material weaknesses in internal controls over financial reporting.
• Implement additional internal procedures and utilize external consulting resources to enhance internal controls.
• Pursue the appeal of the Nasdaq delisting decision and take necessary steps to regain compliance with Nasdaq listing rules.
• Monitor relevant events and conditions and update assumptions and allowance for credit losses on the Marizyme Notes.
• Evaluate cybersecurity needs and develop appropriate measures to enhance cybersecurity posture.
• Consider engaging external cybersecurity experts, conducting vulnerability assessments, and developing an incident response strategy.
• Establish a cybersecurity framework commensurate with the company's size, complexity, and operations.
• The Board (or designated committee or officer) will receive periodic updates on cybersecurity risks.
• Vigorously defend against the lawsuit filed by Lifesci Capital LLC.

Key Dates

Recommendation

Keywords

Qualigen Therapeutics, QLGN, Oncology, Cancer Treatment, QN-302, Pan-RAS, G-quadruplexes, RAS oncogene, Clinical Trial, Preclinical, Biotechnology, Pharmaceuticals, SEC Filing, 10-K, Financial Report, Going Concern, Capital Raise, Nasdaq Delisting, Corporate Governance, Risk Factors, DuraGraft, Marizyme, Orphan Drug Designation, Internal Controls